Morphin 100 Retard (Morphine Sulfate)

Morphine sulfate, the active ingredient in Morphin 100 Retard, is an opioid analgesic presented as a 100 mg prolonged‑release tablet for oral use. It treats moderate to severe acute pain, post‑operative pain, cancer‑related pain and chronic severe pain when other analgesics are insufficient.

GNH USA supplies Morphin 100 Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Morphin 100 Retard is an opioid analgesic used for conditions that require strong, sustained pain relief.

- Moderate to severe acute pain: provides continuous analgesia for patients with intense short‑term pain. - Post‑operative pain: maintains pain control after surgical procedures when oral therapy is appropriate. - Cancer‑related pain: offers long‑acting relief for malignant disease‑associated discomfort.

Morphin 100 Retard may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness - Dry mouth - Sweating

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Adrenal insufficiency - Serotonin syndrome - Anaphylactic reaction - Opioid dependence or addiction

When prescribing or dispensing Morphin 100 Retard, consider the following safety measures.

- Assess pain severity: ensure opioid therapy is clinically justified. - Evaluate respiratory function: monitor patients with compromised breathing. - Review substance‑use history: identify risk of misuse or dependence. - Adjust dose in renal or hepatic impairment: start low and titrate cautiously. - Monitor for excessive sedation or confusion: especially in elderly patients. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Morphin 100 Retard can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise morphine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect. - Other opioids or opioid‑containing products: risk of additive sedation. - Anticholinergic agents: may exacerbate constipation. - Diuretics: can enhance orthostatic hypotension.